Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Michalakopoulou 176, 11527 Athens, Greece.
Laboratory of Medical Biology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Dig Liver Dis. 2021 May;53(5):574-580. doi: 10.1016/j.dld.2020.11.030. Epub 2020 Dec 16.
Several studies correlated elevated B-cell activating factor (BAFF) levels and its polymorphisms (SNPs) in patients with autoimmunity. Limited data existed regarding the role of BAFF in Crohn's Disease (CD) susceptibility and/or treatment response to infliximab.
This study aims to evaluate BAFF expression in CD patients, investigate if its expression can predict response to infliximab treatment, and examine the association of BAFF SNPs with CD susceptibility.
One hundred twelve CD patients and 164 healthy controls were recruited. Serum BAFF levels were determined using an enzyme-linked immunosorbent assay. Participants were genotyped for rs9514828, rs1041569 and rs2893321 SNPs.
Serum BAFF concentration was elevated in CD patients (472.86 ± 223.60 pg/ml) compared with controls (128.16 ± 70.10 pg/ml) before treatment. Responders to IFX treatment had increased serum BAFF levels at baseline (610.03 ± 167.55 pg/ml) compared to non-responders (267.09 ± 107 pg/ml). In responders, BAFF concentration reduced after IFX administration, while increased in non-responders. The rs1041569, TA and AA genotypes frequencies, and the minor allele A were increased significantly in CD patients, indicating an association of the SNP with CD susceptibility.
Our study suggests that BAFF could be a potential biomarker of CD, while SNP rs1041569 was associated with CD susceptibility.
多项研究表明，自身免疫患者的 B 细胞激活因子（BAFF）水平升高及其多态性（SNP）与其相关。关于 BAFF 在克罗恩病（CD）易感性和/或英夫利昔单抗治疗反应中的作用，仅有有限的数据。
本研究旨在评估 CD 患者的 BAFF 表达，探讨其表达是否可预测英夫利昔单抗治疗的反应，并研究 BAFF SNP 与 CD 易感性的关系。
招募了 112 名 CD 患者和 164 名健康对照者。采用酶联免疫吸附试验测定血清 BAFF 水平。对 rs9514828、rs1041569 和 rs2893321 SNP 进行基因分型。
与对照组（128.16±70.10 pg/ml）相比，治疗前 CD 患者的血清 BAFF 浓度升高（472.86±223.60 pg/ml）。IFX 治疗的应答者在基线时的血清 BAFF 水平升高（610.03±167.55 pg/ml），而非应答者的水平较低（267.09±107 pg/ml）。在应答者中，IFX 给药后 BAFF 浓度降低，而非应答者则升高。CD 患者的 rs1041569、TA 和 AA 基因型频率以及次要等位基因 A 明显增加，表明该 SNP 与 CD 易感性相关。
本研究表明 BAFF 可能是 CD 的潜在生物标志物，而 SNP rs1041569 与 CD 易感性相关。
